Medicus Pharma reported Q2 2026 financial results highlighting progress in its SkinJect and Teverelix drug programs, including FDA and UAE approvals for key studies. The company raised about $40 million through equity and debt in H1 2026, improving its cash position to $25.2 million. Despite increased operating expenses and a net loss of $11.7 million, Medicus is advancing toward late-stage development with plans for further clinical milestones and strategic partnerships. The company also noted the need for additional financing to sustain operations.
The Bank of Japan increased its benchmark interest rate by 25 basis points to 1.25%, the highest level in 31 years, to combat persistent inflation and a weak yen. Despite the hike, the yen weakened against the dollar, while Bitcoin prices rose, refle...
Zcash developers have set November 5 as the target date for the NU7 mainnet upgrade, which will reduce block times from 75 to 25 seconds and disable version 4 transactions, stopping spending from legacy Sprout funds. The upgrade aims to improve trans...
Aruma Resources Ltd announced encouraging first assay results from its Phase 2 diamond drilling at the Tillex Copper-Silver Project in Ontario, confirming the extension of shallow, high-grade copper mineralisation. The latest drilling expanded the kn...
U.S. spot ether ETFs experienced net outflows for the third consecutive day, losing about $39 million on Thursday despite Ether's 2% price rise to $2,470. Meanwhile, Bitcoin ETFs attracted roughly $159 million, pushing Bitcoin above $77,000. Zcash ou...
AeroVironment is evolving from a tactical drone maker into a comprehensive defense technology platform by integrating autonomy, software, and counter-drone capabilities. Despite reporting a $265 million GAAP net loss mainly due to a $240.7 million go...
